This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Teleflex (TFX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 22.03% and 1.27%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Oct 29 Earnings Roster: SYK, BAX & More
by Trina Mukherjee
Medical Product companies have shown strength in the third quarter on the back of huge adoption of COVID-19 related healthcare-support products and services despite the impact of the ongoing pandemic.
Earnings Preview: Teleflex (TFX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teleflex's (TFX) Arrow EZ-IO Gets FDA's Expanded Indications
by Zacks Equity Research
Teleflex's (TFX) recent expanded indications for its IO device provide more time to physicians to establish safe vascular access.
How Has TFX Performed 30 Days Post Earnings
by Zacks Equity Research
Teleflex (TFX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
TeleFlex Banks on Urolift Sales Amid Coronavirus-Led Debacle
by Zacks Equity Research
The acquired business of Teleflex (TFX), NeoTract has been performing impressively lately.
Teleflex (TFX) Beats Q2 Earnings Estimates, Margins Contract
by Zacks Equity Research
Teleflex (TFX) sales grow within the Americas attributable to Vascular Access and respiratory products, driven by COVID-19-led elevated demand.
Teleflex (TFX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 55.65% and 6.46%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
OPKO Health (OPK) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
OPKO Health's (OPK) second-quarter results are likely to reflect solid performance from Products segment and RAYALDEE.
Medical Products Stock Earnings on Jul 30: BAX, SYK & More
by Trina Mukherjee
Despite the impact of the pandemic on the second quarter, Medical Product companies have shown strength on the back of huge adoption of COVID-19 related healthcare-support products and services.
Teleflex (TFX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Teleflex (TFX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Teleflex (TFX) on robust segmental and geographical growth.
Why Is Teleflex (TFX) Up 8.2% Since Last Earnings Report?
by Zacks Equity Research
Teleflex (TFX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Teleflex (TFX) Rides on UroLift Sales Amid Coronavirus Mayhem
by Zacks Equity Research
NeoTract, the acquired business of Teleflex (TFX), continues to perform impressively.
Teleflex (TFX) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Teleflex's (TFX) first-quarter 2020 results reflect sales growth across few major segments despite the coronavirus pandemic.
Teleflex (TFX) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 18.26% and 1.98%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Earnings on Apr 30: BAX, IDXX & More
by Zacks Equity Research
The medical product companies have partially mitigated the impact of the pandemic driven by the massive adoption of COVID-19 related healthcare-support products and services.
Teleflex (TFX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to Teleflex (TFX) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Teleflex (TFX) on its strong segmental and international growth in the fourth quarter of 2019.
4 MedTech Stocks Set to Rebound Post Coronavirus-Led Crisis
by Zacks Equity Research
Here are some MedTech stocks which are steadily inching toward a trend reversal after registering record declines over the past few weeks.
Teleflex (TFX) Down 36.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Teleflex (TFX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Teleflex (TFX) on its strong segmental and international performance in Q4.
Teleflex (TFX) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Teleflex's (TFX) fourth-quarter 2019 results reflect strong segmental performances.
Teleflex COMFORT FLO System's Voluntary Recall Ranked Class I
by Zacks Equity Research
Teleflex's (TFX) COMFORT FLO Humidification System up for worldwide voluntary recall after the receipt of complaints of device malfunction.
Teleflex's Bipolar Temporary Pacing Guidewire Gets FDA Nod
by Zacks Equity Research
Teleflex (TFX) receives the FDA clearance for its bipolar temporary pacing guidewire, thus paving the way for improvements in TAVR and BAV procedures.